AI
Sunday, April 12, 2026 2:49:37 PM
mCRC poster abstract :
Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
This is the abstract for the mCRC poster -- 21 APR ( Clinical Correlates of Immunotherapy )
Conclusions: Leronlimab combined with TAS-102 and bevacizumab is feasible, showing promising early biomarker and clinical activity in heavily pretreated mCRC. Universal CCR5 positivity supports CCR5 as a potential therapeutic target. Updated outcomes and correlative data will be presented.
Preliminary results of a phase 2 study of leronlimab in combination with TAS-102 and bevacizumab in previously treated metastatic colorectal cancer
This is the abstract for the mCRC poster -- 21 APR ( Clinical Correlates of Immunotherapy )
Conclusions: Leronlimab combined with TAS-102 and bevacizumab is feasible, showing promising early biomarker and clinical activity in heavily pretreated mCRC. Universal CCR5 positivity supports CCR5 as a potential therapeutic target. Updated outcomes and correlative data will be presented.
